KALA BIO (KALA) Stock Price, News & Analysis

Company Overview

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions. These include formulations under development for dry eye disease and post-operative ocular inflammation, each leveraging the company’s nanoparticle platform to achieve higher local drug concentrations while potentially reducing systemic exposure. Preclinical and clinical programs are also exploring additional indications in retinal and anterior segment disorders.

Founded in 2014 and headquartered in Watertown, Massachusetts, KALA Bio conducts research and development activities primarily in the United States. The company collaborates with academic institutions, specialty pharmacies and contract research organizations to support its clinical programs and regulatory filings. To broaden its global footprint, KALA Bio is evaluating strategic partnerships for potential expansion into European and Asian markets.

Key Stats

• Today's Range: $1.51 to $1.60
• 50-Day Range: $1.36 to $19.63
• 52-Week Range: $1.10 to $20.60
• Volume: 421,922 shs
• Average Volume: 2.71 million shs
• Market Capitalization: $10.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.38
• Consensus Rating: Hold

KALA BIO Stock Analysis - MarketRank™

KALA BIO scored higher than 82% of companies evaluated by MarketBeat, and ranked 178th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

KALA BIO has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

Upside Potential

KALA BIO has a consensus price target of $20.38, representing about 1,214.5% upside from its current price of $1.55.

Amount of Analyst Coverage

KALA BIO has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of KALA BIO is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KALA BIO is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KALA BIO has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.40% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 54.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KALA BIO does not currently pay a dividend.

Dividend Growth

KALA BIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.35

Percentage of Shares Shorted

11.40% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 54.96%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: -0.19

News Sentiment

KALA BIO has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for KALA BIO this week, compared to 2 articles on an average week.

Search Interest

29 people have searched for KALA on MarketBeat in the last 30 days. This is an increase of 164% compared to the previous 30 days.

MarketBeat Follows

6 people have added KALA BIO to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,055,659.00 in company stock.

Percentage Held by Insiders

Only 8.32% of the stock of KALA BIO is held by insiders.

Percentage Held by Institutions

Only 24.61% of the stock of KALA BIO is held by institutions.

KALA Stock Analysis - Frequently Asked Questions

How have KALA shares performed this year?

KALA BIO's stock was trading at $6.94 at the beginning of 2025. Since then, KALA shares have decreased by 77.7% and is now trading at $1.55.

How were KALA BIO's earnings last quarter?

KALA BIO, Inc. (NASDAQ:KALA) posted its quarterly earnings data on Friday, August, 8th. The company reported ($1.71) EPS for the quarter, topping the consensus estimate of ($1.82) by $0.11.

When did KALA BIO's stock split?

Shares of KALA BIO reverse split on the morning of Friday, October 21st 2022.The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did KALA BIO IPO?

KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

How do I buy shares of KALA BIO?

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of KALA BIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KALA
• CIK: 1479419
• Web: www.kalarx.com
• Phone: (781) 996-5252
• Fax: 781-642-0399
• Employees: 30
• Year Founded: 2009

Price Target and Rating

• Average Price Target for KALA BIO: $20.38
• High Price Target: $35.00
• Low Price Target: $1.50
• Potential Upside/Downside: +1,214.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -686.43%
• Return on Assets: -76.81%

Debt

• Debt-to-Equity Ratio: 3.19
• Current Ratio: 2.10
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 2.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.02 per share
• Price / Book: 0.77

Miscellaneous

• Outstanding Shares: 7,020,000
• Free Float: 6,437,000
• Market Cap: $10.88 million
• Optionable: Not Optionable
• Beta: -2.10